Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Article activity feed

1. Version published to 10.1038/s41586-021-03739-1

   Jun 30, 2021
2. 

   Version published to 10.21203/rs.3.rs-428630/v1 on Research Square

   Apr 19, 2021
3. 

   ScreenIT

   Mar 1, 2021

   SciScore for 10.1101/2021.02.03.21251054: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: The study was approved by the East of England – Cambridge Central Research Ethics Committee (17/EE/0025).
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   PBMCs were stained with 2ul of each antibody: anti-CD3-fluorescein isothiocyanate (FITC), clone UCHT1; anti-CD4-phycoerythrin (PE), clone RPA-T4; anti-CD8a-peridinin-chlorophyll	anti-CD3-fluorescein suggested: None anti-CD4-phycoerythrin suggested: None anti-CD8a-peridinin-chlorophyll suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Virus …

   SciScore for 10.1101/2021.02.03.21251054: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: The study was approved by the East of England – Cambridge Central Research Ethics Committee (17/EE/0025).
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   PBMCs were stained with 2ul of each antibody: anti-CD3-fluorescein isothiocyanate (FITC), clone UCHT1; anti-CD4-phycoerythrin (PE), clone RPA-T4; anti-CD8a-peridinin-chlorophyll	anti-CD3-fluorescein suggested: None anti-CD4-phycoerythrin suggested: None anti-CD8a-peridinin-chlorophyll suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Virus neutralisation assays were performed on 293T cell transiently transfected with ACE2 and TMPRSS2 using SARS-CoV2 Spike pseudotyped virus expressing luciferase23.	293T suggested: None
   Software and Algorithms
   Sentences	Resources
   Data were analysed with FlowJo v10 (Becton Dickinson, Wokingham, UK).	FlowJo suggested: (FlowJo, RRID:SCR_008520)
   Developed plates were read using an AID iSpot reader (Oxford Biosystems, Oxford, UK) and counted using AID EliSpot v7 software (Autoimmun Diagnostika GmbH, Strasberg, Germany).	Oxford Biosystems suggested: (Science Exchange, RRID:SCR_010620)
   IC50 values were calculated in GraphPad Prism.	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   Here we have addressed an important aspect of rollout of vaccination against SARS-CoV-2, where the second dose may be delayed due to supply limitations. We have shown that almost half of individuals above the age of 80 have a suboptimal neutralising antibody response three weeks after vaccination with BNT162b2, and that the second dose is associated with robust neutralising responses. T cell responses were generally good across age groups following first dose, though lower in the over 80 age group. Binding IgA antibodies to Spike and RBD increased following the first and second doses, mirroring levels seen in natural infection. IgG3 responses to Spike and RBD increased predominantly after the second dose; this subclass has been associated with multifunctional antibody responses. In a clinical study specifically looking at older adults vaccinated with BNT162b2 the GMT (geometric mean titre) after first dose was 12 in a set of 12 subjects between ages of 65 and 85 years, rising to 149 seven days after the second dose 3. Whilst the GMT after second dose was lower in older subjects, the data for first dose were unclear, possibly due to neutralisation assay characteristics. Furthermore, in the Moderna 1273 mRNA vaccine study in older individuals (above 55 years), neutralisation was only detectable after the second dose, whilst binding antibodies were detectable after both doses9. Interestingly, in aged mice the ChAdOx nCov-19 vaccine responses were lower as compared to younger mic...

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
4. 

   Version published to 10.1101/2021.02.03.21251054 on medRxiv

   Feb 5, 2021